Current Report Filing (8-k)
15 10월 2016 - 5:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
October 12, 2016
ZOSANO PHARMA CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36570
|
|
45-4488360
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
34790 Ardentech Court
Fremont, CA 94555
(Address of principal executive offices) (Zip Code)
(510) 745-1200
Registrants telephone number, including area code
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 3.01
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On
October 12, 2016, Zosano Pharma Corporation (the Company) received written notice from The NASDAQ Stock Market, LLC (NASDAQ) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement
for continued listing on The NASDAQ Capital Market, as set forth in Listing Rule 5550(a)(2). In accordance with Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until April 10, 2017, to regain compliance with the
minimum bid price requirement. To regain compliance, the closing bid price of the Companys common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-day period.
If the Company is not in compliance by April 10, 2017, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the
Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, except for the minimum bid price requirement. In addition, the
Company would be required to notify NASDAQ of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split.
If the Company does not regain compliance within the allotted compliance periods, including any extensions that may be granted by NASDAQ, NASDAQ will provide
notice that the Companys common stock will be subject to delisting. The Company would then be entitled to appeal the NASDAQ Staffs determination to a NASDAQ Listing Qualifications Panel and request a hearing.
The Company intends to monitor the closing bid price of its common stock and consider options to resolve the noncompliance with the minimum bid price
requirement. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other NASDAQ listing criteria.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ZOSANO PHARMA CORPORATION
|
|
|
|
|
October 14, 2016
|
|
|
|
By:
|
|
/s/ Georgia Erbez
|
|
|
|
|
|
|
Name: Georgia Erbez
|
|
|
|
|
|
|
Title: Chief Business Officer and Interim Chief Financial Officer
|
3
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Zosano Pharma Corporation (나스닥)의 실시간 뉴스: 최근 기사 0
More Zosano Pharma Corp News Articles